Rigetti Computing, Inc.
INVESTMENT VIEW
Scientific momentum is real; cash burn and valuation overwhelm proven commercial scale
Rigetti achieved 99.5% median two-qubit fidelity on its 108-qubit system. However, Q3 revenue fell 28% YoY to US$1.41M while the operating loss reached US$33.19M.
The report rates the shares Sell. The key distinction is technology progress versus monetization: a US$3.8B market value still depends on commercial outcomes well beyond reported sales.
KEY DATA
| Market capitalization | ~US$3.81B |
|---|---|
| 11 Nov closing price | US$11.11 |
| Trading volume, 11 Nov | 33.06M |
| TTM revenue (vendor) | US$12.82M |
| Q3 2026 revenue | US$1.41M |
| Q3 operating loss | (US$33.19M) |
| Cash + investments | US$497.1M |
| Trailing P/E | N.M. (loss-making) |
| P/B, 30 Sep basis | 7.03x |
| FY2026 revenue guide | ~US$20M* |
QUARTERLY REVENUE TREND
CATALYSTS / RISKS
| 99.5% gate fidelity | Cash burn / dilution |
|---|---|
| Up-to-$100M award | Revenue recognition |
| System milestones | High P/S valuation |
*11 Nov close; P/B uses 30 Sep book value. FY26 guidance depends on C-DAC acceptance. Sources: issuer Q3 release and SEC 10-Q.
A full-stack superconducting quantum platform with early commercial traction
Rigetti sells quantum processors, on-premises systems and cloud access; unit economics and repeat demand remain unproven.
BUSINESS MODEL AND REVENUE SOURCES
| BUSINESS LAYER | HOW ECONOMICS ARE GENERATED |
|---|---|
| On-premise systems | Cepheus 36–108 qubit systems, Novera QPUs and associated hardware. |
| Cloud access (QCaaS) | Remote quantum computing access and system services. |
| Research contracts | Government, research and collaborative R&D engagements. |
| Platform roadmap | Chiplets, proprietary fabrication, control electronics and orchestration. |
INVESTMENT THESIS
Positive: superconducting chiplet technology and a 108-qubit system meeting the 99.5% median two-qubit fidelity milestone. Rigetti has a cash and short-term securities buffer and a U.S. government R&D agreement that may support development.
Constraint: quarterly revenue is lumpy and tiny relative to research spending. The latest quarter had US$1.41M sales against US$34.04M of operating expenses; the company is years away from demonstrated earnings-based valuation.
Conclusion: technical optionality merits monitoring, not an unqualified premium. The source research assessment selects Sell (3–6 months), with reassessment contingent on customer acceptance, new orders and cash-flow improvement.
Quarterly revenue fell even as the nine-month revenue base doubled
A one-quarter GAAP net loss of only US$3.1M masks a US$33.2M operating deficit and warrant-related gains.
Q3 2026 VERSUS PRIOR YEAR
| METRIC | Q3 2026 | Q3 2025 | READ-THROUGH |
|---|---|---|---|
| Revenue | US$1.411M | US$1.947M | −27.5% |
| Gross profit | US$0.857M | US$0.404M | +112% |
| R&D spending | US$25.495M | US$15.020M | +70% |
| SG&A spending | US$8.548M | US$5.933M | +44% |
| Operating loss | (US$33.186M) | (US$20.549M) | Wider |
| GAAP net loss | (US$3.137M) | (US$200.968M) | Distorted |
| Non-GAAP net loss | (US$20.5M) | — | Still negative |
OPERATING-TO-GAAP EARNINGS BRIDGE
Operating loss was US$33.186M. Interest income added US$4.758M and a US$25.291M non-cash fair-value gain on derivative warrant liabilities offset much of the operating loss. Reported GAAP net loss of US$3.137M therefore is not evidence that core operations approached break-even.
REVENUE CADENCE — RECENT FOUR COMPARABLE OBSERVATIONS
Nine-month revenue rose to US$10.949M (+110% YoY), but Q3 revenue was only 13% of the nine-month total. Large system-acceptance events can create pronounced quarterly volatility.
Liquidity remains significant; underlying cash use accelerated
The correct cash-burn measure is operating cash consumption plus capital expenditure, not the net change in cash.
NINE MONTHS THROUGH 30 SEPTEMBER
| MEASURE | 9M 2026 | CONTEXT / 9M 2025 |
|---|---|---|
| Net operating cash used | (US$49.06M) | (US$43.64M) |
| Capital expenditure | (US$42.60M) | (US$14.10M) |
| Simple FCF (CFO − capex) | (US$91.66M) | (US$57.75M) |
| Change in fair value of warrants | +US$49.39M | Non-cash income |
| Stock-based compensation | US$20.87M | Added back in CFO |
| Maturing securities | US$322.00M | Investing cash inflow |
| New securities purchases | (US$229.33M) | Investing outflow |
CASH CONVERSION AND CAPITAL INTENSITY
Operating cash burn rose about 12% versus 9M2025. Capital expenditure roughly tripled to US$42.6M, principally for fabrication and quantum systems infrastructure. Simple FCF burn reached US$91.7M, about 59% greater than the US$57.7M comparable 2025 period.
Annualizing 9M2026 FCF burn yields roughly US$122M. Comparing that mechanically with US$497M liquidity produces about four years of coverage; this is not management guidance and excludes an expanding equipment roadmap, working-capital movements and financing changes.
No borrowing debt, but sizable liabilities and equity dilution matter
Approximately US$497M of liquid resources coexist with meaningful warrant-related liabilities and persistent cash burn.
SEPTEMBER 2026 BALANCE-SHEET SNAPSHOT
| Cash and cash equivalents | US$45.80M |
|---|---|
| Short-term marketable securities | US$337.51M |
| Long-term marketable securities | US$113.83M |
| Cash + all marketable securities | US$497.14M |
| Total current assets | US$406.62M |
| Total current liabilities | US$76.82M |
| Derivative warrant liabilities | US$53.09M |
| Total liabilities | US$81.98M |
| Shareholders’ equity | US$541.97M |
| Current ratio | 5.29× |
CAPITAL STRUCTURE AND U.S. GOVERNMENT AGREEMENT
In September the Department of Commerce entered an agreement for an award of up to US$100M for quantum research programs. As a transaction inducement, Rigetti issued 7,739,938 common shares to the Department. This award is conditional and should not be mistaken for unrestricted third-quarter revenue.
Issued shares increased to 342.70M by 30 September 2026 from 331.28M at 31 December 2025 (+3.4%). Issued equity can fund a technology roadmap but also dilutes economic ownership; monitor any future ATM issuance and share-based incentives.
The scientific milestone is material, but not equivalent to commercial advantage
System-scale fidelity is improving; the technology still needs customer workloads that justify procurement and repeat use.
VERIFIED MILESTONES & MEDIUM-TERM ROADMAP
| PROGRAM | COMPANY REPORTED STATUS |
|---|---|
| 108 qubits | 99.5% median two-qubit fidelity achieved on 12 × 9-qubit chiplets. |
| 80 / 50 sublattices | Company cites 99.6% / 99.7% median two-qubit fidelity. |
| Mid-2028 target | 300+ qubits, ~99.7% fidelity, sub-60ns two-qubit gates. |
| Longer-horizon aspiration | ~1,000 qubits and ~99.9% fidelity in about three years. |
| U.S. CHIPS support | Up-to-$100M agreement for readout, cryogenics and fabrication R&D. |
COMPETITIVE CONTEXT — DIFFERENT MODALITIES
Superconducting approaches face competition from IBM and Google’s quantum programs and from ion-trap, neutral-atom, photonic and annealing architectures. Hardware specifications are not directly comparable without uniform tests of gate quality, circuit depth, error correction and useful workloads.
COMMERCIAL TESTS THAT MATTER MORE THAN QUBIT HEADLINE
- External workloads and benchmark reproducibility, not only internal calibration results.
- Paid systems delivered and accepted by customers; recognition timing and acceptance conditions.
- Gross margin and support cost per delivered system as the customer base scales.
- Evidence of recurring cloud or system-service consumption beyond demonstration contracts.
The equity value prices a dramatic future scaling outcome
A pre-profit quantum supplier cannot be assessed using a normal P/E multiple; revenue- and cash-based checks expose the implied growth burden.
MARKET MULTIPLES ON A CONSISTENT REFERENCE BASIS
| VALUATION MEASURE | READING | BASIS / CAVEAT |
|---|---|---|
| Completed close | US$11.11 | 11 Nov 2026 |
| Shares outstanding | 342.70M | 30 Sep 2026 filed basis |
| Illustrative market capitalization | ~US$3.81B | price × filed shares |
| TTM revenue | US$12.82M | vendor snapshot; approximate |
| Market cap / TTM sales | ~297× | based on rounded TTM revenue |
| Book value per share | ~US$1.581 | 30 Sep equity / shares |
| Price / book | ~7.03× | 11 Nov price / filed BVPS |
| P/E and forward P/E | N.M. | Loss-making; negative multiple unhelpful |
WHAT REVENUE SCALE WOULD BE NEEDED?
Holding the ~US$3.81B equity capitalization unchanged, the table shows the revenue required at alternative sales multiples. This is a sensitivity framework, not a price target.
| P/S | NEEDED ANNUAL SALES | SCALE IMPLICATION |
|---|---|---|
| 300× | US$12.7M | Approximately current trailing scale |
| 100× | US$38.1M | ~1.9× FY26 management guide |
| 50× | US$76.1M | ~3.8× FY26 management guide |
| 25× | US$152.3M | ~7.6× FY26 management guide |
| 10× | US$380.7M | ~19.0× FY26 management guide |
A premium may be rational if commercialization arrives rapidly. The critical risk is that current equity valuation is several hundred times trailing sales while operating cash flow is negative.
A rebound attempt remains below the key trend-repair levels
The source’s 12 November US$10.73 is an in-session snapshot; US$11.11 is the latest completed regular-session close.
COMPLETED-SESSION PRICE ACTION
TECHNICAL REFERENCE MATRIX
| INDICATOR | VALUE | INTERPRETATION |
|---|---|---|
| 11 Nov completed close | $11.11 | −8.56% day; 33.06M volume |
| 12 Nov source snapshot | $10.73 | In-session; not official close |
| 10 EMA / Bollinger middle | $11.46 / $11.57 | First recovery thresholds |
| 50-day moving average | $13.68 | Medium-term trend remains bearish |
| RSI / MACD | 41.15 / −0.67 | Sub-neutral momentum |
| Lower / upper Bollinger | $10.15 / $12.98 | Downside / upside volatility guides |
| Average true range (ATR) | $1.05 | ~9.8% of $10.73 snapshot |
High discount rates and weak sentiment magnify execution risk
For a small revenue, loss-making quantum issuer, capital-market conditions matter disproportionately to the valuation multiple.
MACRO AND FINANCING TRANSMISSION
| DRIVER | SOURCE SNAPSHOT | IMPACT FOR RGTI |
|---|---|---|
| U.S. 10-year yield | 4.88%* | Raises discount rate for distant profits |
| Federal funds effective | 3.88%* | Restricts funding/risk appetite |
| U.S. inflation backdrop | Sticky* | Reduces odds of rapid multiple expansion |
| AI/frontier-compute rotation | Volatile | Narrative sympathy can overwhelm near-term revenues |
RECENT COMPANY EVENTS
10 November: Rigetti reported Q3 2026 financials and 99.5% median two-qubit gate fidelity on its 108-qubit system. The results highlighted a US$33.2M operating loss despite scientific progress.
September: up-to-US$100M Department of Commerce research award, accompanied by issuance of approximately 7.74M shares. A milestone-based R&D agreement is not an immediately collectible sales contract.
SENTIMENT QUALITY
The supplied social-media sample includes 13 bearish, 4 bullish and 13 unlabeled StockTwits messages. This is a small, biased retail sample—not an institutional consensus. Other news and Reddit coverage was unavailable. Subsequent official earnings and SEC filings provide stronger factual evidence than social chatter.
*Macro levels from the dated 12 Nov research snapshot; not represented as an independently verified intraday Treasury closing print.
Sell reflects present risk/reward, not a denial of scientific progress
The research assessment proposes reducing or exiting, with 3–6 months as the reassessment horizon.
BULL / BASE / BEAR SCENARIO CARDS
BULL
Commercial proof arrives
C-DAC system acceptance converts into reported Q4 revenue; new contracts add visibility, 108Q performance stimulates orders.
Evidence: revenue recognition, declining burn, sustained price above $11.57.
BASE
Valuation remains narrative-led
R&D milestones continue but quarterly sales and cash flow remain volatile; the stock trades in wide ranges.
Evidence: mixed orders and limited trend repair; sub-normal weight.
BEAR
Losses outlast funding optimism
Acceptance delayed, capex continues, investors demand a lower sales multiple; further dilution becomes a consideration.
Evidence: failed recovery and renewed pressure near $10.15.
POSITIONING FROM RESEARCH ASSESSMENT
The primary source decision is SELL, not Underweight. It favors a substantial reduction or exit; if maintaining thematic exposure, restrict it to a small, explicitly speculative residual position. Do not upgrade merely because a rebound follows oversold conditions.
| Current position above normal risk budget | Trim or exit; avoid averaging down into weak trend. |
|---|---|
| No current position | Observe; do not treat a large price drawdown as cheap valuation. |
| First technical reassessment | Sustained recovery above $11.46–11.57; momentum improvement. |
| Fundamental reassessment | Recognized system revenue, customer expansion, narrower cash burn. |
With negative normalized EPS, a strict Davis classification is not available
Share-price direction and one-time GAAP profit effects do not substitute for a comparable positive EPS/P/E series.
Q1
EPS UP / P-E DOWN
Earnings improve while valuation contracts.
Q2
EPS UP / P-E UP
Davis Double Play: earnings and multiple rise.
Q3
EPS DOWN / P-E DOWN
Davis Double Kill: earnings and multiple fall.
Q4
EPS DOWN / P-E UP
Earnings weaken while valuation expands.
CURRENT EVIDENCE AND CLASSIFICATION
- Core operations remain loss-making: Q3 operating loss US$33.19M; nine-month operating loss US$87.20M.
- Q3 GAAP results include a non-cash US$25.29M warrant valuation benefit. GAAP EPS is not a clean normalized earnings trend.
- A meaningful TTM P/E is unavailable with negative earnings. Market capitalization divided by sales is a more informative, but incomplete, reference.
- The appropriate Davis verdict is UNCONFIRMED / NOT APPLICABLE, rather than forcing the company into Quadrant 3.
Five investment conclusions and the evidence needed to change them
The source rating is Sell; official SEC and issuer figures take precedence over vendor-based valuation and cash-flow labels.
FIVE INVESTMENT TAKEAWAYS
- Technology: the 108Q 99.5% median two-qubit fidelity milestone is meaningful scientific progress, not proof of broad customer adoption.
- Sales: Q3 revenue declined 28% YoY; FY2026 revenue around US$20M depends on C-DAC customer acceptance in Q4.
- Earnings quality: core operating losses and cash burn are more consequential than a favorable noncash warrant mark.
- Financial resilience: US$497.1M liquid resources and no borrowing debt create runway, but recurring R&D and capex consume capital.
- Valuation: roughly 297× trailing sales and 7.03× book leave limited margin for error on commercialization timing.
THREE DECISION TRIGGERS
| MONITOR | WHAT WOULD CHANGE THE ASSESSMENT |
|---|---|
| Upgrade the fundamental case | Signed, delivered and accepted systems lead to sustained revenue and reduced cash burn. |
| Upgrade the technical case | Prices hold above $11.46–11.57 and positive trend/momentum signals follow. |
| Reinforce the Sell case | Guide is missed, support erodes, or capital investment grows faster than new commercial wins. |